| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, August 2007, p. 5534-5543, Vol. 27, No. 15
0270-7306/07/$08.00+0 doi:10.1128/MCB.00302-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1590,1 Laboratory Research Program, Transgenic Mouse Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-15902
Received 19 February 2007/ Returned for modification 7 May 2007/ Accepted 16 May 2007
| ABSTRACT |
|---|
|
|
|---|
subunit of the intestinal Gs protein (Gs
), leading to characteristic water and electrolyte losses. Mammalian cells contain ADP-ribosyltransferases similar to CT and an ADP-ribosyl(arginine)protein hydrolase (ADPRH), which cleaves the ADP-ribose-(arginine)protein bond, regenerating native protein and completing an ADP-ribosylation cycle. We hypothesized that ADPRH might counteract intoxication by reversing the ADP-ribosylation of Gs
. Effects of intoxication on murine ADPRH/ cells were greater than those on wild-type cells and were significantly reduced by overexpression of wild-type ADPRH in ADPRH/ cells, as evidenced by both ADP-ribose-arginine content and Gs
modification. Similarly, intestinal loops in the ADPRH/ mouse were more sensitive than their wild-type counterparts to toxin effects on fluid accumulation, Gs
modification, and ADP-ribosylarginine content. Thus, CT-catalyzed ADP-ribosylation of cell proteins can be counteracted by ADPRH, which could function as a modifier gene in disease. Further, our study demonstrates that enzymatic cross talk exists between bacterial toxin ADP-ribosyltransferases and host ADP-ribosylation cycles. In disease, toxin-catalyzed ADP-ribosylation overwhelms this potential host defense system, resulting in persistence of ADP-ribosylation and intoxication of the cell. | INTRODUCTION |
|---|
|
|
|---|
subunit of the Gs protein (Gs
) (8). Like other G proteins, Gs
is active with bound GTP. Its intrinsic GTPase activity converts the active GTP-bound protein to the inactive GDP-bound species (34). Because the Gs
catalytic arginine is critical for GTP hydrolysis to GDP and thereby inactivation, ADP-ribosylation of that arginine inhibits GTPase activity and prolongs the lifetime of active, GTP-bound Gs
(3, 9, 42). The resulting persistent activation of adenylyl cyclase increases cyclic AMP (cAMP) accumulation, along with its effects on water and electrolyte transport that cause the diarrhea of cholera (7, 33). In addition to CT, other bacterial toxin ADP-ribosyltransferases utilize arginine residues in proteins as ADP-ribose acceptors (8). Escherichia coli heat-labile enterotoxin acting by a mechanism very similar to that of CT is responsible for some cases of traveler's diarrhea (22). Pseudomonas aeruginosa exoenzyme S, a cytotoxin introduced into cells via a type III secretory system, modified free arginine and arginine in the signaling protein Ras (5, 10). Another P. aeruginosa cytotoxin, exoenzyme T, modified arginine 20 in Crk (CT10 regulator of kinase) (6), affecting the actin cytoskeleton. Clostridial C2 toxin ADP-ribosylates an arginine in actin (40), resulting in displacement of the equilibrium toward depolymerization, with adverse effects on cytoskeletal organization and chemotaxis. Other bacterial protein products, such as Clostridium perfringens iota toxin (41) and Salmonella enterica SpvB cytotoxin (14), also use an arginine in actin as an ADP-ribose acceptor. Of note, bacteriophage T4 modifies arginine (36). Based on these observations, modification of arginine in critical cellular proteins appears to be a common mechanism for toxin disruption of signal transduction pathways and cytoskeletal regulation.
Mammalian cells contain ADP-ribosyltransferases that, like CT and other cytotoxins, catalyze the stereospecific transfer of ADP-ribose from ß-NAD to the guanidino moiety of arginine to generate
-ADP-ribosylarginine (26, 32). Several NAD:arginine ADP-ribosyltransferases have been purified from avian or mammalian tissues, and their cDNAs have been cloned (12, 29, 30, 39, 45). In mammalian cells, ADP-ribosylation appears to be a reversible posttranslational modification of proteins (23, 30, 43). An ADP-ribosylarginine hydrolase (ADPRH) that cleaves the ribosylarginine linkage, generating the unmodified protein (23, 25, 27), can complete a potentially regulatory ADP-ribosylation cycle. Such a cycle is thus far best documented in the photosynthetic bacterium Rhodospirillum rubrum, where it controls the activity of dinitrogenase reductase, a key enzyme in nitrogen fixation (20). Mammalian cells may similarly use transferase and hydrolase enzymes for controlling their content of ADP-ribose-arginine in proteins.
ADPRHs in humans and rodents are
39-kDa proteins that share some amino acid identity (37). Only one hydrolase has been identified in mammalian tissues, consistent with the existence of only one ADP-ribose-arginine hydrolase gene (2). Its function, presumably, is to reverse the action of the ADP-ribosyltransferase and thereby regulate cellular levels of proteins containing ADP-ribose-arginine (30, 43). We asked whether the hydrolase can also counteract the effects of CT on cells, by removing ADP-ribose from the modified Gs
protein. To evaluate this possibility, we studied the small intestine (and other cells) from knockout (KO) mice that lacked hydrolase activity. Sensitivity to CT was assessed by determining the extent of modification of Gs
and the levels of ADP-ribosyl(arginine)protein. The toxin effects on fluid accumulation in intestinal loops were much greater in KO than wild-type mice. Data from experiments with cells grown from mouse embryos were similarly consistent with the conclusion that the hydrolase can, indeed, moderate the effects of CT both in vitro and in vivo.
| MATERIALS AND METHODS |
|---|
|
|
|---|
were kindly provided by Lee Weinstein (NIDDK, NIH). Animal studies. Animal protocols were approved by the National Heart, Lung, and Blood Institute, National Institutes of Health Animal Care and Use Committee (9-PCCM-4R, 2-PCCMB-30, and 3-PCCMB-30). ADPRH mice were backcrossed seven times using C57BL/6J mice (Jackson Laboratory, Bar Harbor, MI).
Preparation of targeting vector and ES cells.
A targeting vector was prepared to delete a 1.0-kb DNA fragment of the mouse ADPRH gene between XhoI and BamHI sites, which includes exon 2; the deleted region includes D60 and D61 critical for catalytic activity (18). A
13-kb SalI genomic fragment was cloned from a genomic library of 129/SvJ mice in a Lambda FIX II vector (Stratagene, La Jolla, CA), and from it, a
7-kb EcoRI fragment containing exons 1 and 2 was subcloned into pGEM 3Z. A 4.5-kb fragment comprising the 5' flanking region, exon 1, and part of intron 1 was excised from the 7-kb EcoRI fragment with EcoRI and XhoI and subcloned into the scrambler A region of pKO Scrambler vector (Stratagene). A 1.8-kb fragment containing part of intron 2 was amplified by PCR (primers are listed in Table 1) with the 7-kb EcoRI fragment in pGEM 3Z as a template and subcloned into scrambler B region of the pKO Scrambler vector. Neomycin resistance and thymidine kinase genes in the targeting vector were used, respectively, as positive and negative selection markers of homologous recombination. The unique SalI site was used to linearize the pKO vector before electroporation of embryonic stem (ES) cells. Clones resistant to both G418 (Sigma, St. Louis, MO) and ganciclovir (Sigma) were analyzed by Southern blotting. Wild-type and targeted ADPRH alleles were found in, respectively, 11- and 6-kb bands and 6.7- and 5.8-kb bands by Southern blotting of the ES cell genomic DNA digested with PstI and hybridized with a 5' probe (490-bp; 360 to 130, including exon 1), and SacI and hybridized with 3' probe (360-bp; positions 5053 to 5412, including exon 3) (Table 1).
|
Southern blot analysis.
Samples (5 to 10 µg) of genomic DNA prepared from ES cells or mouse tails using a Wizard genomic DNA purification kit (Promega) according to standard protocols were digested with PstI or SacI (Roche, Indianapolis, IN), subjected to electrophoresis in 1.0% agarose gel, and transferred (Turboblotter system; Schleicher & Schuell, Keene, NH) to nylon membrane (S & S Nyrtan; Schleicher & Schuell). The 5' and 3' cDNA probes corresponding to bases in the mouse ADPRH genomic DNA had been amplified from a 129/SvJ mouse genomic library in a Lambda FIX II vector (Stratagene), using specific primers (Table 1). Membranes were incubated for 1 h at 68°C in ExpressHyb (BD Clontech, Palo Alto) with [
-32P]dATP (Perkin Elmer, Boston, MA)-labeled probes (Table 1) located outside the 5'- and 3'-flanking regions of the targeting vector (Fig. 1). Membranes were washed twice for 20 min at room temperature with 2x SSC-0.1% sodium dodecyl sulfate (SDS) (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and twice for 30 min at 60°C with the same solution before exposure to film. 32P was detected by exposure of X-ray film (Kodak, Rochester, NY).
|
-32P]dATP (Perkin Elmer) was used as a probe. After hybridization for 1 h at 68°C in ExpressHyb (BD Clontech) with heat-denatured salmon sperm DNA (100 mg/ml) and [
-32P]dATP-labeled 291-bp probes, membranes were washed twice with 2x SSC-0.1% SDS at room temperature for 20 min and twice with 0.2x SSC-0.1% SDS at 60°C for 20 min before exposure to film. 32P was detected by exposure to X-ray film (Kodak). After the blot was stripped to remove the labeled probe, the blot was hybridized with a ß-actin cDNA probe (Ambion, Austin, TX). Construction of wild-type and mutant mouse ADPRH expression vectors. ADPRH wild-type cDNA was amplified from mouse brain cDNA library (BD Clontech) with forward and reverse primers (Table 1). Fragments were excised with HindIII and BamHI or with BamHI and SmaI, respectively, digested for ligation into a pcDNA4/V5-His (Invitrogen) or pGEX-2T (Amersham Bioscience, Piscataway, NJ) vector to produce the recombinant wild-type plasmid. Pfu polymerase (Stratagene) was used for PCR (Perkin-Elmer Thermal Cycler 9600) amplification according to the manufacturer's protocol for 35 cycles of 95°C for 45 s, 60°C for 45 s, and 72°C for 2.5 min. Mutant ADPRH (D60A, D61A) that lacks hydrolase activity was generated using a QuikChange site-directed mutagenesis kit (Stratagene) with oligonucleotide primers (Table 1) according to the manufacturer's protocol. After amplification, supercoiled double-stranded DNA was digested (2 h at 37°C; total volume, 50 µl) with DpnI endonuclease (2.5 units), which is specific for methylated and hemimethylated DNA. DNA isolated from almost all E. coli strains is dam-methylated and therefore susceptible to DpnI digestion. The nicked vector DNA, containing the mutant hydrolase, was transfected into Epicurian Coli XL1-Blue supercompetent cells, which were plated on LB-ampicillin agar plates and incubated at 37°C overnight. For each mutant, 20 colonies were grown overnight individually in 3 ml of LB-ampicillin at 37°C. Plasmid cDNA was isolated by a QIAprep spin miniprep kit (QIAGEN, Studio City, CA), and the entire coding region was sequenced (ABI PRISM 377; Perkin-Elmer). Finally, pcDNA4/V5-His and pGEX-2T vectors, each containing wild-type and mutant ADPRH cDNAs, were prepared.
Production of GST fusion wild-type and double-mutant ADPRH proteins by pGEX-2T. Wild-type and mutant recombinant ADPRH (rADPRH) proteins were synthesized in E. coli BL21 during incubation at 30°C for 12 h in the presence of 0.2 mM isopropyl-ß-D-thiogalactopyranoside (total volume, 100 ml) (18, 25). Cells were harvested, washed with ice-cold phosphate-buffered saline (PBS), pH 7.4, and suspended in 5 ml of lysis buffer (10 mM sodium phosphate, 10 mM EDTA, pH 8.0). After repeated freezing (on dry ice for 5 min) and thawing at room temperature (three times) and sonification for 1 min on ice, the cell lysate was centrifuged (4,000 x g for 20 min), and the supernatant was incubated (gentle agitation at room temperature for 30 min) with 2 ml of glutathione-Sepharose 4B (50% slurry in PBS). The matrix was washed with 20 ml of PBS before elution of glutathione S-transferase (GST)-bound proteins in 4 ml of 10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0, which was concentrated to a final volume of 1 ml using a p30 Microcon (Millipore, Billerica, MA). Samples (0.15 ml) were mixed with 0.05 ml of 4x SDS sample buffer (4% SDS, 10% glycerol, 0.08% bromophenol blue, 2% ß-mercaptoethanol, 125 mM Tris-HCl, pH 6.8), boiled for 5 min, and subjected to electrophoresis in a 12% Tris-glycine gel (Invitrogen), followed by staining with 0.05% Coomassie blue. Fusion proteins were estimated to be 95% pure by SDS-polyacrylamide gel electrophoresis (PAGE) (data not shown). The expression of wild-type and mutant ADPRH was confirmed with Western blot analysis and ADPRH assay.
Transfection and clonal selection of ADPRH/ cells. ADPRH/ cells from a 14.5-day embryo were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% (newborn calf serum) NBCS and transformed with pcDNA4/V5-His, pcDNA4/V5-His wild-type, or mutant vectors using Fugene 6 (Roche) transfection reagent. After culture for 2 to 3 weeks with zeocin (1 mg/ml; Invitrogen) as a selection reagent, single colonies were grown in 96-well plates to confirm the presence of rADPRH wild-type or mutant proteins with Western blot analyses and ADPRH assays. ADPRH/ cells expressing ADPRH wild-type cDNA are designated ADPRH/* and ADPRH/ cells expressing the ADPRH mutant protein are designated ADPRH/**. After selection, these reconstituted (rescued) ADPRH cells were grown in DMEM supplemented with 10% NBCS, penicillin (10,000 units/ml), streptomycin (10 mg/ml), and zeocin (1 mg/ml) (Invitrogen) at 37°C in a humidified atmosphere with 5% CO2.
Western blot analysis.
ADPRH protein was quantified by Western blotting. Protein (20 µg) from each cell lysate was subjected to SDS-PAGE, transferred to nitrocellulose membranes, and reacted with rabbit anti-ADPRH polyclonal antibodies, or rabbit anti-Gs
polyclonal antibodies. A detection kit, SuperSignal West Pico Chemiluminescent Substrate (Pierce), was used for visualization of immunocomplexes. Blots were stripped according to the manufacturer's instructions before another reaction with antibodies. An anti-glyceraldehyde-3-phosphate dehydrogenase (Chemicon, Temecula, CA) blot was treated in parallel to monitor loading and effects of stripping. Antibodies were detected by exposure of X-ray film (Kodak) with detection using an LAS-3000 bioimaging system (Fuji, Tokyo).
ADPRH assay. ADPRH activity of embryonic cells, transformed cells, and mouse tissues was assayed, as described previously (18). The substrate was synthesized in a reaction catalyzed by 50 µg of CT A subunit (List Biological Laboratory), with 2 mM ß-NAD, 2 mM [14C]arginine (50 µCi; Sigma), 20 mM dithiothreitol, 50 mM potassium phosphate (pH 7.5), and 30 µg of ovalbumin in a total volume of 0.3 ml during incubation at 30°C overnight. ADP-ribosyl-[14C]arginine was purified by high-performance liquid chromatography (Hewlett-Packard series 1100 system equipped with a diode-array spectrophotometric detector set at 260 nm) using an anion exchange column (Zorbax SAX; 4.6-mm inner diameter; Rockland Technologies, Newport, DE) and elution with a linear gradient of NaCl (0 to 1 M) in 20 mM sodium phosphate buffer, pH 4.5, for 30 min at a flow rate of 1 ml/min. ADP-ribosyl-[14C]arginine eluted at 11 to 12 min and separated from arginine and nicotinamide (which eluted between 3 and 6 min), NAD (17 to 19 min), and ADP-ribose (38 to 39 min). ADP-ribosyl-[14C]arginine was lyophilized, dissolved in 50 µl of H2O, and stored at 20°C. Samples (100 µg) of homogenized tissue (ADPRH+/+, ADPRH+/, and ADPRH/), proteins (40 µg) from homogenized cells (ADPRH+/+, ADPRH+/, and ADPRH/ embryonic cells and ADPRH/* and ADPRH/** transformed cells), or purified recombinant mouse ADPRH proteins (50 ng) (wild-type and mutant ADPRH) synthesized as GST-fusion proteins were assayed in 50 mM potassium phosphate, pH 7.5, containing 5 mM dithiothreitol, 10 mM MgCl2, 50 µM ADP-ribosyl-[14C]arginine (6,000 cpm) (total volume, 100 µl). After 1 h at 37°C, a sample (90 µl) was applied to a column (0.8 by 4 cm) of Affi-Gel boronate (Bio-Rad, Hercules, CA), equilibrated, and eluted with 5 ml of 0.1 M glycine, pH 9.0, 0.1 M NaCl, and 10 mM MgCl2. Total eluate was counted by a liquid scintillation counter. For calculation of ADPRH activity, ADP-ribose values were corrected for the activity present at time zero and in replicate assays without enzyme.
Culture of mouse embryo cells. Fibroblasts were prepared from embryonic day 14.5 embryos as described previously (38). In brief, a skin sample (5 to 7 mg) was washed in 7.5 ml of PBS with gentle shaking in a 15-ml polypropylene tube. Subcutaneous tissue was removed from the skin sample by scraping the dermal surface using pairs of forceps before it was incubated in 0.25% trypsin-PBS for 30 min at 37°C. The skin samples were then placed on a 100-mm dish, epidermis was removed by scraping, and tissue was washed in the same way before being cut into 2- to 4-mm squares on the 100-mm tissue culture dish. Skin pieces (5 to 7 pieces) were placed in each well of a six-well plate; 5 min later, DMEM (Invitrogen) supplemented with 10% NBCS was added carefully to avoid to disturbing the tissue, followed by incubation at 37°C in a humidified atmosphere of 5% CO2. Fibroblast outgrowth was monitored every 2 days using an inverted phase-contrast microscope, and when cells were confluent, cells were washed twice with ice-cold PBS, harvested using 0.05% trypsin-EDTA, and plated on collagen I-coated 100-mm dishes (passage 1 cells). Cell culture was continued in the same way for more than 21 passages in DMEM with 10% NBCS in an atmosphere of 5% CO2. Samples of cells for stock at passages 2 to 15 were frozen in Cell Banker (Wako Chemical USA, Richmond, VA) and stored at 80°C. For experiments, thawed cells were grown in DMEM supplemented with 10% NBCS, penicillin (10,000 units/ml), and streptomycin (10 mg/ml) (Invitrogen) at 37°C in a humidified atmosphere of 5% CO2.
Preparation of proteins from cultured cells and mouse tissues. For experiments with CT, cultured cells (passages 6 to 10) from exponentially dividing stock cultures (3.0 x 105 cells per 150-mm dish) were grown to ca. 80% confluence and incubated in DMEM medium without serum for 24 h. Cells were incubated with 100 ng/ml CT (List Biological Laboratory, Campbell, CA) in 10 ml of DMEM containing 10% NBCS for 6 h; then, medium was discarded, and cells were rinsed twice with ice-cold PBS, pH 7.4, before the addition of 5 ml of 20% ice-cold trichloroacetic acid (TCA) (Sigma). After 20 min at 4°C, contents of dishes were scraped with a Cell Lifter (Corning, Corning, NY) into 1.5-ml tubes, which were centrifuged (20,000 x g for 30 min at 4°C). Supernatants were discarded, and pellets were washed once with 20% ice-cold TCA and twice with ether; residual ether was removed under vacuum, and the pellets were stored at 80°C.
Animal tissues were rapidly excised and immediately frozen in liquid nitrogen and pulverized as described previously (16). After evaporation of liquid nitrogen, 2 ml of ice-cold 20% (wt/vol) TCA was added, and the tissue was homogenized using 30 strokes of a Dounce all-glass, hand homogenizer (Kontes, Vineland, NJ) on ice. Insoluble material was pelleted by centrifugation (20,000 x g at 30 min for 4°C), and supernatants were discarded; pellets were washed once with cold 20% TCA and twice with ether; residual ether was removed under vacuum, and the powder was stored at 80°C.
Solubilization of TCA-precipitated proteins. TCA-precipitated proteins in 2 ml of TENDS buffer (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM NaN3, 2 mM dithiothreitol, 0.25 M sucrose) with 0.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 0.5 mM benzamidine, and a 10 µg/ml concentration of leupeptin, aprotinin, and trypsin inhibitor were homogenized on ice in a 4°C room using 30 strokes of a Dounce all-glass, hand homogenizer (Kontes). Protein was quantified using a Micro-BCA protein assay reagent kit (Pierce, Rockford, IL), according to the manufacturer's protocol.
In vivo CT treatment and in vitro rADPRH treatment. TCA-precipitated proteins from cultured cells in CT experiments were homogenized in TENDS buffer on ice in a 4°C room, using 30 strokes of a Dounce all-glass hand homogenizer (Kontes). After homogenization, samples (total, 30 µg of protein) were incubated with 0.5 µg of rADPRH protein (0.5 µg/µl) or 0.5 µg of bovine serum albumin (0.5 µg/µl) at 30°C for 1 h in vitro. After incubation, 5 µl of 4x SDS sample buffer was added directly to each sample tube for Western blot analysis.
Fluid accumulation induced by CT. Fluid accumulation induced by CT was quantified using mouse intestinal loops, as described previously (13). ADPRH+/+, ADPRH+/, and ADPRH/ (male and female) mice (20 to 25 g; 6 to 8 weeks old) had access to water ad libitum but no food for 12 h before experiments. Mice were anesthetized by inhalation of 1 to 3% isoflurane, and the intestine was exteriorized through a midline incision. In each mouse, 2 or 3 intestinal segments (ca. 4 cm) were separated by ligation with nylon suture. PBS (0.2 ml) without or with CT (0.5 µg) or 5 mM 8-bromo-cAMP was injected into each loop. The abdomen was closed, and 0.5% bupivacaine (2 to 3 drops) was applied to the incision while the mouse recovered from anesthesia on a 37°C mat. Mice were monitored until euthanized with CO2 via gas cylinders after being placed in a desiccator jar or equivalent. Weight and length of each intestinal loop with its contents were recorded. Fluid accumulation in the ligated loops, reflecting CT action, is reported as weight per length (mg/cm); data are presented as means ± standard errors of the means (SEMs) of values from six experiments.
Assay of ADP-ribosylarginine in cells. ADP-ribosylarginine content of cultured cells, intestinal loops, and their epithelial cells was quantified using TCA-precipitated proteins that had been stored at 80°C. TCA-precipitated proteins (4.0 mg) were dissolved in 2 ml of 6 M guanidinium chloride, 50 mM morpholinepropanesulfonic acid, and 10 mM EDTA, pH 4.0, with 30 strokes of a Dounce all-glass hand homogenizer (Kontes) on ice. A 0.5-ml aliquot of each sample was subjected to analysis as described previously (16). All assays were performed in triplicate, and data represent means of values from six experiments.
Densitometry and statistics. The bands were analyzed by the densitometric quantification of proteins on blots. We used a LAS 3000 Bioimaging system with the image analysis software Image Gauge, version 4.0 (Fuji). Data are presented as means ± SEMs of values from the indicated number of experiments or samples. Student's t test was used to evaluate differences, with a P value of <0.05 considered to be significant.
| RESULTS |
|---|
|
|
|---|
ADPRH proteins and activity in KO and heterozygous mice and embryonic cells. ADPRH mRNA was not detected by Northern blot analysis of ADPRH/ mice (Fig. 1D) with an exon 2-specific probe (Table 1). Absence of the ADPRH gene product was confirmed by immunoblotting and activity measurements. By Western analysis, no immunoreactive protein was detected in KO mouse tissues. Amounts of the 39-kDa ADPRH were less in lysates of intestine from heterozygous than from wild-type mice (Fig. 1E). No hydrolase activity was detected in intestinal lysates from ADPRH/ mice, and activity was significantly lower in those from heterozygous than from wild-type mice (Fig. 1F).
Mice were interbred to generate litters with ADPRH+/+, ADPRH+/, and ADPRH/ mice from the heterozygous intercrosses (ADPRH+/+:ADPRH+/:ADPRH/ in males 46:80:54 and in females, 44:84:48) with a typical litter size of 8 to 10 pups, indicating that the ADPRH mutation is not embryonic lethal.
The embryonic ADPRH/ cells were transfected with cDNA to overexpress wild-type ADPRH or a mutant in which D60 and D61, amino acids that are critical for hydrolase activity, were replaced by alanine. Immunoblotting with antibodies against ADPRH revealed considerably less 39-kDa hydrolase in ADPRH+/ than ADPRH+/+ cells and none in ADPRH/ cells. Both ADPRH/* and ADPRH/** cells overexpressing wild-type and inactive mutant ADPRH, respectively, showed immunoreactive 39-kDa hydrolase bands. ADPRH/ cells had no measurable hydrolase activity, and ADPRH+/ cells exhibited
30% of the activity of wild-type ADPRH+/+ cells (Fig. 2A). After transfection, activity of ADPRH/* cells expressing wild-type hydrolase was 80% of wild-type cells, whereas overexpression of the inactive mutant enzyme in ADPRH/** cells did not increase significantly the activity of ADPRH/ cells (Fig. 2A).
|
in ADPRH/ embryonic cells and ADPRH/ cells reconstituted with wild-type or mutant ADPRH.
To determine the effects of ADPRH activity on intoxication of cells by CT, wild-type, heterozygous, KO, and KO cells overexpressing wild-type or inactive mutant ADPRH genes were incubated with CT before evaluation by immunoblotting to detect alterations in Gs
, the major intracellular toxin substrate. These cells contained both 45- and 52-kDa forms of Gs
. CT-catalyzed ADP-ribosylation decreases the mobility of modified Gs
, seen in the KO cells after 2 h of toxin exposure, where the amount of 52-kDa Gs
was also markedly reduced (Fig. 2B). Continued accumulation of ADP-ribose Gs
was not seen, presumably because the modified protein is degraded, as reported previously (4). The data are consistent with release of the ADP-ribose from Gs
by ADPRH in wild-type and heterozygous cells but not in ADPRH/ cells at a rate sufficient to largely reverse CT-catalyzed ADP-ribosylation. The mobility of Gs
was similar in all cells not exposed to toxin, whether KO or KO cells reconstituted with wild-type or mutant hydrolase, and amounts of Gs
were in general greater than those in toxin-treated cells.
The loss of Gs
following incubation of cells with CT was dependent on time of incubation of cells with toxin and occurred earlier in the KO than in the wild-type cells, consistent with their more extensive modification (Fig. 2B). Cells reconstituted with the mutant hydrolase exhibited an intermediate response. This observation is consistent with the finding that the mutant possesses some hydrolase activity. The amount of hydrolase per cell basis is similar to the amount of ADP-ribose-arginine in the cells, perhaps explaining why a relatively inactive mutant can be effective in modulating ADP-ribosylation (data not shown).
Effect of CT on ADP-ribosylarginine content of ADPRH/ embryonic cells and ADPRH/ cells reconstituted with wild-type or mutant ADPRH.
Consistent with the greater extent of modification of Gs
by toxin in ADPRH/ cells, we found that the KO cell content of ADP-ribose-arginine protein was significantly higher than that of wild-type cells, both before and after incubation with CT (Fig. 3A). These data show that the more extensive modification of Gs
by toxin in KO cells was associated with enhanced accumulation of total ADP-ribose-(arginine)protein; absence of the hydrolase also resulted in elevated basal ADP-ribose-(arginine)protein. Lower levels of both basal and CT-catalyzed ADP-ribose-(arginine)protein were associated with overexpression of wild-type or mutant ADPRH in KO cells (Fig. 3A). Similar to the extent of modification of Gs
by CT in the heterozygous cells, KO cells overexpressing the mutant hydrolase had an ADP-ribose-(arginine)protein content intermediate between those of KO and wild-type cells. It was more similar to that of the wild-type than the KO cells, perhaps because the mutant hydrolase does have catalytic activity, albeit less than 0.01% that of the wild-type enzyme.
|
in ADPRH KO and wild-type cells.
It was possible that the effects on the electrophoretic mobility of Gs
seen in KO cells did not result from ADP-ribosylation of arginine but from some other alteration of the protein. To explore this possibility, lysates of CT-treated KO and wild-type cells were incubated with purified recombinant ADPRH synthesized in E. coli. After incubation with hydrolase, the mobility of Gs
from KO cells resembled that of the protein from untreated wild-type cells (Fig. 3B), consistent with the conclusion that ADP-ribosylation was responsible for the observed changes in migration of protein on SDS-PAGE.
Effect of Gs
and fluid accumulation in CT and ADPRH genotype on intestinal loops.
The mouse intestinal loop model has been used extensively to investigate effects of CT and other enteric toxins (13). Accumulation of fluid following injection of toxin into a loop results in increased weight and distention of the intestinal segment. The effect of CT on fluid accumulation was quantified every 2 h and clearly increased with time; differences between wild-type and KO intestinal loops were evident (Fig. 4A). Differences in the behavior of Gs
in KO and wild-type intestinal loops after CT treatment were also notable. The extensive modification of the Gs
seen in KO lysates was not apparent in the wild-type (Fig. 4C), indicating that the CT effects were greatly magnified in KO mice.
|
|
in epithelial cells from KO loops incubated with toxin for 6 h was less than that of Gs
in wild-type tissue. The amount of Gs
detected by immunoblotting decreased significantly with time of exposure of tissue to CT (Fig. 5B). To determine whether the lower mobility resulted from ADP-ribosylation or some other modification, membranes after toxin treatment were incubated with recombinant hydrolase in the presence of Mg2+ and/or dithiothreitol. As seen in the KO cell experiments (Fig. 3B), incubation with hydrolase converted the modified Gs
from the KO loops to a protein with mobility similar to that of the protein from control loops (data not shown). The ADP-ribose-(arginine)protein content of loops from KO mice without toxin exposure was significantly greater than that of the loops from the wild-type mice (Fig. 5C). Similarly, following incubation with toxin, the ADP-ribose-(arginine)protein content in loops from KO mice exceeded that of loops from the wild-type animals (Fig. 5C). Further, the ADP-ribose-(arginine)protein content of the epithelial cells isolated from mutant loops, incubated either with or without CT, greatly exceeded that of intact mutant loops (Fig. 5C). Thus, the observations with the KO and wild-type loops are in agreement with the findings from the related cultured cells. The studies support a role for hydrolase in determining cell sensitivity to CT. | DISCUSSION |
|---|
|
|
|---|
seen by Western blotting were greater in KO than wild-type cells. Both were decreased in KO cells by overexpression of wild-type hydrolase but not an inactive mutant. In the intestinal loop assay, CT effects, as quantified by fluid accumulation, were greater in the KO than the wild-type mice, but the responses to cAMP, the "second messenger" that is elevated by CT as it is by physiological agonists that activate adenylyl cyclase, were identical in KO and wild-type tissues.
CT increases adenylyl cyclase activity, leading to an increase in cellular cAMP through ADP-ribosylation and activation of Gs
, which, in turn, activates the adenylyl cyclase catalytic unit. The effects of CT may differ in KO and wild-type cells, since in wild-type cells ADPRH is present and can cleave the ADP-ribose-(arginine)Gs
modification to some extent, reversing CT effects. This reaction does not occur in ADPRH/ cells, and hence the response to CT is greater. Since cAMP is downstream of ADP-ribose Gs
, its effects are independent of ADPRH.
CT has NAD glycohydrolase as well as NAD:arginine ADP-ribosyltransferase activity (24, 28). In addition to modifying a specific arginine in its "true" substrate, i.e., the one that is responsible for its pathogenicity, the toxin can ADP-ribosylate guanidine and other arginine moieties in a number of proteins (28). In this regard, CT is similar to mammalian transferases that can ADP-ribosylate arginine in a variety of proteins (30). In cultured cells and membrane preparations, Gs
appears to be the protein that is predominantly modified (8), as demonstrated here for both the intestinal loops and cells.
Specific intracellular protein substrates for the hydrolase have not been defined. In vitro, hydrolase exhibits a broad substrate specificity and can cleave ADP-ribose attached to arginines in a number of proteins, including Gs
(21, 30, 43). In the latter instance, however, although recombinant hydrolase was shown to cleave ADP-ribose-Gs
, the enzyme was present in
8- to 20-fold molar excess over substrate, and under these extreme conditions, only a fraction of the ADP-ribosylated Gs
was cleaved. In our studies as well, a large excess of hydrolase was necessary to observe cleavage of ADP-ribosyl-Gs
. These in vitro data would suggest that ADP-ribosylated Gs
is a poor hydrolase substrate. The in vivo results are, therefore, surprising in that the KO genotype had a marked effect on tissue content of ADP-ribose-Gs
and ADP-ribose-arginine as well as fluid accumulation, consistent with a major role for hydrolase in the wild-type mouse. Indeed, in vitro activity appears to have been an unreliable predictor of in vivo findings. In vitro results cannot be extrapolated to in vivo effects of hydrolase, perhaps due to the localization of hydrolase in the intestinal epithelial cells or the activation of the hydrolase in the cellular environment. It remains to be seen whether the action of other bacterial toxin ADP-ribosyltransferases may be modified by specific cellular hydrolases.
The hydrolase enzymatic activity is dependent on two aspartate residues at positions 60 and 61 (18); their replacement with alanine results in a dramatic reduction in activity to <0.01% of that the intact enzyme, although the mutant protein appears structurally intact and retains its ability to bind ADP-ribose. It can, therefore, serve as a control for hydrolase function in overexpression experiments. KO cells overexpressing the mutant hydrolase had an ADP-ribose-(arginine)protein content intermediate between that of KO and wild-type cells. It seemed surprising that they were more similar to the wild-type than to the KO cells. In fact, the differences between cells expressing mutant and wild-type hydrolase were not statistically significant, whereas the difference between KO cells and cells expressing mutant hydrolase were statistically significant (Fig. 3A). Thus, the low residual activity of the mutant may be sufficient to alter the responsiveness of the cells to CT. On reflection, however, although mutant enzyme activity is less than 0.01% that of the wild-type hydrolase, the amount of overexpressed protein is similar on a molar basis to the ADP-ribose-(arginine)protein content of the cell. Thus, even a single turnover could be adequate to reverse some amount of CT-catalyzed modification and delay the accumulation of ADP-ribose-(arginine)protein in intoxicated cells.
Because only one ADPRH gene has thus far been identified in human and rodent tissues, it was not surprising that hydrolase KO mice exhibited enhanced sensitivity to CT, although cells do contain enzymes that might metabolize ADP-ribosylated proteins in different reactions. ADP-ribose is subject to cleavage of the AMP-phosphoribosyl bond by pyrophosphatases, which would generate phosphoribosylated protein (1, 19, 35). Phosphoribose can be hydrolyzed by phosphatases, which would yield a ribosylarginine(protein). Degradation of ADP-ribosylarginine in proteins could occur as a result of ADPRH activity or the combined action of pyrophosphatases and phosphatases. Alternatively, disappearance of ADP-ribose Gs
may result from rapid degradation by a proteolytic pathway. In KO cells and tissues with increased amounts of ADP-ribosylated proteins, the destruction of Gs
was apparently accelerated. These findings are consistent with prior findings (4) that CT-catalyzed ADP-ribosylation of Gs
resulted in degradation of the protein. Presumably, the decrease in Gs
content alters the responses of cells to hormones and the function of other signaling pathways that intersect or are influenced by those dependent on Gs
.
The accumulation of ADP-ribosylated Gs
in the KO mice was presumably a result of failure, in the absence of ADPRH, to cleave the ribosyl-guanidino bond at a rate equal to that of its synthesis by CT. It appears that the hydrolase was important in counteracting CT-catalyzed ADP-ribosylation and that the greater persistence of CT-modified Gs
in the KO than wild-type cells resulted in accelerated loss of Gs
. The plasma membrane of epithelial cells contains substantial numbers of ganglioside GM1 molecules, which bind toxin and thus facilitate ADP-ribosylation of Gs
(15). In disease, presumably, the capacity of cells to counteract intoxication by hydrolysis of the ADP-ribose-arginine linkage is overwhelmed. The data support the conclusion that the hydrolase might serve as a modifier gene in cholera and perhaps other diseases caused by toxin ADP-ribosyltransferases.
| ACKNOWLEDGMENTS |
|---|
antibodies. We also thank Martha Vaughan and Vincent Manganiello for helpful discussions and critical review of the manuscript. This research was supported by the Intramural Research Program at the National Heart, Lung, and Blood Institute, National Institutes of Health.
| FOOTNOTES |
|---|
Published ahead of print on 25 May 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Aoki, K., J. Kato, M. T. Shoemaker, and J. Moss. 2005. Genomic organization and promoter analysis of the mouse ADP-ribosylarginine hydrolase gene. Gene 351:83-95.[CrossRef][Medline]
3. Cassel, D., and Z. Selinger. 1977. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc. Natl. Acad. Sci. USA 74:3307-3311.
4. Chang, F. H., and H. R. Bourne. 1989. Cholera toxin induces cAMP-independent degradation of Gs. J. Biol. Chem. 264:5352-5357.
5. Coburn, J., and D. M. Gill. 1991. ADP-ribosylation of p21ras and related proteins by Pseudomonas aeruginosa exoenzyme S. Infect. Immun. 59:4259-4262.
6. Deng, Q., J. Sun, and J. T. Barbieri. 2005. Uncoupling Crk signal transduction by Pseudomonas exoenzyme T. J. Biol. Chem. 280:35953-35960.
7. Field, M., D. Fromm, Q. al-Awqati, and W. B. Greenough III. 1972. Effect of cholera enterotoxin on ion transport across isolated ileal mucosa. J. Clin. Investig. 51:796-804.[Medline]
8. Fishman, P. H. 1990. Mechanism of action of cholera toxin, p. 127-140. In J. Moss, and M. Vaughan, (ed.), ADP-ribosylating toxins and G proteins: insights into signal transduction. ASM Press, Washington, DC.
9. Freissmuth, M., and A. G. Gilman. 1989. Mutations of Gs alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity. J. Biol. Chem. 264:21907-21914.
10. Ganesan, A. K., D. W. Frank, R. P. Misra, G. Schmidt, and J. T. Barbieri. 1998. Pseudomonas aeruginosa exoenzyme S ADP-ribosylates Ras at multiple sites. J. Biol. Chem. 273:7332-7337.
11. Gill, D. M. 1976. The arrangement of subunits in cholera toxin. Biochemistry 15:1242-1248.[CrossRef][Medline]
12. Glowacki, G., R. Braren, K. Firner, M. Nissen, M. Kuhl, P. Reche, F. Bazan, M. Cetkovic-Cvrlje, E. Leiter, F. Haag, and F. Koch-Nolte. 2002. The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. Protein Sci. 11:1657-1670.
13. Hitotsubashi, S., Y. Fujii, H. Yamanaka, and K. Okamoto. 1992. Some properties of purified Escherichia coli heat-stable enterotoxin II. Infect. Immun. 60:4468-4474.
14. Hochmann, H., S. Pust, G. von Figura, K. Aktories, and H. Barth. 2006. Salmonella enterica SpvB ADP-ribosylates actin at position arginine-177-characterization of the catalytic domain within the SpvB protein and a comparison to binary clostridial actin-ADP-ribosylating toxins. Biochemistry 45:1271-1277.[CrossRef][Medline]
15. Holmgren, J., I. Lonnroth, J. Mansson, and L. Svennerholm. 1975. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc. Natl. Acad. Sci. USA 72:2520-2524.
16. Jacobson, M. K., D. M. Payne, R. Alvarez-Gonzalez, H. Juarez-Salinas, J. L. Sims, and E. L. Jacobson. 1984. Determination of in vivo levels of polymeric and monomeric ADP-ribose by fluorescence methods. Methods Enzymol. 106:483-494.[Medline]
17. Joyner, A. L. 2000. Gene targeting: a practical approach. Oxford University Press, New York, NY.
18. Konczalik, P., and J. Moss. 1999. Identification of critical, conserved vicinal aspartate residues in mammalian and bacterial ADP-ribosylarginine hydrolases. J. Biol. Chem. 274:16736-16740.
19. Lin, S., L. Gasmi, Y. Xie, K. Ying, S. Gu, Z. Wang, H. Jin, Y. Chao, C. Wu, Z. Zhou, R. Tang, Y. Mao, and A. G. McLennan. 2002. Cloning, expression and characterisation of a human Nudix hydrolase specific for adenosine 5'-diphosphoribose (ADP-ribose). Biochim. Biophys. Acta 1594:127-135.[CrossRef][Medline]
20. Lowery, R. G., and P. W. Ludden. 1990. Endogenous ADP-ribosylation in prokaryotes, p. 459-478. In J. Moss, and M. Vaughan, (ed.), ADP-ribosylating toxins and G proteins: insights into signal transduction. ASM Press, Washington, DC.
21. Maehama, T., H. Nishina, and T. Katada. 1994. ADP-ribosylarginine glycohydrolase catalyzing the release of ADP-ribose from the cholera toxin-modified alpha-subunits of GTP-binding proteins. J. Biochem. (Tokyo) 116:1134-1138.
22. Moss, J., S. Garrison, N. J. Oppenheimer, and S. H. Richardson. 1979. NAD-dependent ADP-ribosylation of arginine and proteins by Escherichia coli heat-labile enterotoxin. J. Biol. Chem. 254:6270-6272.
23. Moss, J., M. K. Jacobson, and S. J. Stanley. 1985. Reversibility of arginine-specific mono(ADP-ribosyl)ation: identification in erythrocytes of an ADP- ribose-L-arginine cleavage enzyme. Proc. Natl. Acad. Sci. USA 82:5603-5607.
24. Moss, J., V. C. Manganiello, and M. Vaughan. 1976. Hydrolysis of nicotinamide adenine dinucleotide by choleragen and its A protomer: possible role in the activation of adenylate cyclase. Proc. Natl. Acad. Sci. USA 73:4424-4427.
25. Moss, J., S. J. Stanley, M. S. Nightingale, J. J. Murtagh, Jr., L. Monaco, K. Mishima, H. C. Chen, K. C. Williamson, and S. C. Tsai. 1992. Molecular and immunological characterization of ADP-ribosylarginine hydrolases. J. Biol. Chem. 267:10481-10488.
26. Moss, J., S. J. Stanley, and N. J. Oppenheimer. 1979. Substrate specificity and partial purification of a stereospecific NAD- and guanidine-dependent ADP-ribosyltransferase from avian erythrocytes. J. Biol. Chem. 254:8891-8894.
27. Moss, J., S. C. Tsai, R. Adamik, H. C. Chen, and S. J. Stanley. 1988. Purification and characterization of ADP-ribosylarginine hydrolase from turkey erythrocytes. Biochemistry 27:5819-5823.[CrossRef][Medline]
28. Moss, J., and M. Vaughan. 1977. Mechanism of action of choleragen. Evidence for ADP-ribosyltransferase activity with arginine as an acceptor. J. Biol. Chem. 252:2455-2457.
29. Okazaki, I. J., H. J. Kim, and J. Moss. 1996. Cloning and characterization of a novel membrane-associated lymphocyte NAD:arginine ADP-ribosyltransferase. J. Biol. Chem. 271:22052-22057.
30. Okazaki, I. J., and J. Moss. 1998. Glycosylphosphatidylinositol-anchored and secretory isoforms of mono-ADP-ribosyltransferases. J. Biol. Chem. 273:23617-23620.
31. O'Neal, C. J., E. I. Amaya, M. G. Jobling, R. K. Holmes, and W. G. Hol. 2004. Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry 43:3772-3782.[CrossRef][Medline]
32. Oppenheimer, N. J. 1978. Structural determination and stereospecificity of the choleragen-catalyzed reaction of NAD+ with guanidines. J. Biol. Chem. 253:4907-4910.
33. Peterson, J. W., and L. G. Ochoa. 1989. Role of prostaglandins and cAMP in the secretory effects of cholera toxin. Science 245:857-859.
34. Price, S. R., A. Barber, and J. Moss. 1990. Structure-function relationships of Guanine nucleotide-binding proteins, p. 397-424. In J. Moss, and M. Vaughan, (ed.), ADP-ribosylating toxins and G proteins: insights into signal transduction. ASM Press, Washington, DC.
35. Ribeiro, J. M., A. Carloto, M. J. Costas, and J. C. Cameselle. 2001. Human placenta hydrolases active on free ADP-ribose: an ADP-sugar pyrophosphatase and a specific ADP-ribose pyrophosphatase. Biochim. Biophys. Acta 1526:86-94.[Medline]
36. Rohrer, H., W. Zillig, and R. Mailhammer. 1975. ADP-ribosylation of DNA-dependent RNA polymerase of Escherichia coli by an NAD+: protein ADP-ribosyltransferase from bacteriophage T4. Eur. J. Biochem. 60:227-238.[Medline]
37. Takada, T., K. Iida, and J. Moss. 1993. Cloning and site-directed mutagenesis of human ADP-ribosylarginine hydrolase. J. Biol. Chem. 268:17837-17843.
38. Takahashi, A. 1998. Establishment of fibroblast cutures, p. 2.1.1-12. In J. S. Bonifacino, M. Dasso, J. B. Harford, J. Lippincotte-schwartz, K. M. Yamada, (ed.), Current protocols in cell biology, vol. I. John Wiley & Sons, Hoboken, NJ.
39. Terashima, M., H. Osago, N. Hara, Y. Tanigawa, M. Shimoyama, and M. Tsuchiya. 2005. Purification, characterization and molecular cloning of glycosylphosphatidylinositol-anchored arginine-specific ADP-ribosyltransferases from chicken. Biochem. J. 389:853-861.[CrossRef][Medline]
40. Vandekerckhove, J., B. Schering, M. Barmann, and K. Aktories. 1988. Botulinum C2 toxin ADP-ribosylates cytoplasmic beta/gamma-actin in arginine 177. J. Biol. Chem. 263:696-700.
41. Vandekerckhove, J., B. Schering, M. Barmann, and K. Aktories. 1987. Clostridium perfringens iota toxin ADP-ribosylates skeletal muscle actin in Arg-177. FEBS Lett. 225:48-52.[CrossRef][Medline]
42. Van Dop, C., M. Tsubokawa, H. R. Bourne, and J. Ramachandran. 1984. Amino acid sequence of retinal transducin at the site ADP-ribosylated by cholera toxin. J. Biol. Chem. 259:696-698.
43. Williamson, K. C., and J. Moss. 1990. Mono-ADP-ribosyltransferases and ADP-ribosylarginine hydrolase: a mono-ADP-ribosylation cycle in animal cells, p. 493-510. In J. Moss, and M. Vaughan, (ed.), ADP-ribosylating toxins and G proteins: insights into signal transduction. ASM Press, Washington, DC.
44. Zhang, R. G., D. L. Scott, M. L. Westbrook, S. Nance, B. D. Spangler, G. G. Shipley, and E. M. Westbrook. 1995. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol. 251:563-573.[CrossRef][Medline]
45. Zolkiewska, A., M. S. Nightingale, and J. Moss. 1992. Molecular characterization of NAD:arginine ADP-ribosyltransferase from rabbit skeletal muscle. Proc. Natl. Acad. Sci. USA 89:11352-11356.
| ||||||||||||||||||||||||||